Related references
Note: Only part of the references are listed.The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells
Sandra A. Bright et al.
BIOCHEMICAL PHARMACOLOGY (2009)
The Novel Tubulin-Targeting Agent Pyrrolo-1,5-Benzoxazepine-15 Induces Apoptosis in Poor Prognostic Subgroups of Chronic Lymphocytic Leukemia
Anthony M. McElligott et al.
CANCER RESEARCH (2009)
Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer
Maulik R. Shah et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia
Alfonso Quintas-Cardama et al.
CLINICAL CANCER RESEARCH (2008)
Homoharringtonine for the treatment of chronic myelogenous leukemia
Alfonso Quintas-Cardama et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315l: from the second to third generation
Ruriko Tanaka et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
SGX393 inhibits the CML mutant Bcr-AblT3151 and preempts in vitro resistance when combined with nilotinib or dasatinib
Thomas O'Hare et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Part II: Management of resistance to imatinib in chronic myeloid leukaemia
Jane FApperley
LANCET ONCOLOGY (2007)
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Jane F. Apperley
LANCET ONCOLOGY (2007)
Intratumor injection of the hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model
Christopher R. Williams et al.
JOURNAL OF UROLOGY (2007)
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Thomas O'Hare et al.
BLOOD (2007)
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
Francois Guilhot et al.
BLOOD (2007)
STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells
Lisa M. Greene et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
Francis J. Giles et al.
BLOOD (2007)
A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia
Rong Chen et al.
CANCER RESEARCH (2006)
Cotreatment with vorinostat (Suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells
Warren Fiskus et al.
CLINICAL CANCER RESEARCH (2006)
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib
Ian J. Griswold et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells
Warren Fiskus et al.
BLOOD (2006)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes et al.
BLOOD (2006)
Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate
TK Nguyen et al.
CLINICAL CANCER RESEARCH (2006)
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy
G Borthakur et al.
CANCER (2006)
Analysis of apoptosis by propidium iodide staining and flow cytometry
Carlo Riccardi et al.
NATURE PROTOCOLS (2006)
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
M Deininger et al.
BLOOD (2005)
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance
K Gumireddy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Selective induction of apoptosis by the pyrrolo-1,5-benzoxazepine 7-[{dimethylcarbamoyl}oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in leukemia cells occurs via the c-jun NH2-terminal kinase-dependent phosphorylation and inactivation of Bcl-2 and Bcl-XL
MM Mc Gee et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo
E Weisberg et al.
LEUKEMIA (2004)
The two major imatinib resistance mutations E255K and T3151 enhance the activity of BCR/ABL fusion kinase
M Yamamoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique (vol 82, pg 284, 2003)
KA Kreuzer et al.
ANNALS OF HEMATOLOGY (2003)
Specific targeted therapy of chronic myelogenous leukemia with imatinib
MWN Deininger et al.
PHARMACOLOGICAL REVIEWS (2003)
Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia
WK Hofmann et al.
BLOOD (2003)
A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia
C Roche-Lestienne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Resistance in the land of molecular cancer therapeutics
KM Shannon
CANCER CELL (2002)
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to ST157, and they can pre-exist to the onset of treatment
C Roche-Lestienne et al.
BLOOD (2002)
Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug
R Capdeville et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
DG Peters et al.
BLOOD (2001)
Share Paper
